HKEX:3681 - SinoMab BioScience Ltd SinoMab BioScience Ltd
Sector: Health Care, Industry: Biotechnology
Add to Watchlist
   
Add Alert 


Yahoo Finance

HKD 1.82    +0.0 (+0%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

7 Dec 2022


Loading...
Loading...
Loading...

General

CEO: Dr. Shui On Leung

Headquarters: HK

Employees: 296

Homepage

Description

SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.

Your Holdings
Dashboard
Portfolio
Options
Other Assets

Tools
Screener
Risk Manager
Other Assets
Watchlist
Alerts
Notes
Wall
Community
Forum
Blogs
Instagram
Facebook
Shared Portfolios
Shared Screeners

Collab with Brokerages
Moomoo x StocksCafe
Webull x StocksCafe
Tiger x StocksCafe

Help
Quickstart Guides
StocksCafe Academy
StocksCafe Youtube Channel

About StocksCafe
Our Story
Send Feedback
Pricing
Market
Singapore
Hong Kong
Tokyo
Kuala Lumpur
United States
London
Shenzhen
Shanghai
Bombay
National (India)
Indexes
Singapore Savings Bonds
Singapore T-Bills
CoinGecko
Your Account
Settings
Subscriptions
Referrals
Messages
Profile
IG    FB    YouTube

About · FAQs · StocksCafe © 2022 · Privacy · Terms